75 POSTER Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors

B.Suttle; S.Saini; S.Kathman; T.Arumugham; B.Whitehead; A.Nixon; H.Hurwitz; A.Dowlati; L.Pandite

首页> 外文期刊>European Journal of Cancer Supplements >75 POSTER Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors

【24h】

75 POSTER Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors

机译：75 POSTER在实体瘤患者（pts）中的药代动力学（PK）-药代动力学相关性，GW酪氨酸激酶抑制剂（TKI）GW786034（帕唑帕尼）的生物学和临床作用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
B.Suttle; S.Saini; S.Kathman; T.Arumugham; B.Whitehead; A.Nixon; H.Hurwitz; A.Dowlati; L.Pandite;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors [J] . G.Dy, G.Croghan, A.Furth, European Journal of Cancer Supplements . 2006,第12期

机译：在晚期实体瘤患者中，将mToR抑制剂依维莫司（RAD001）与两种时间表的血管内皮生长因子（VEGF）酪氨酸激酶抑制剂Vatalanib（PTK787 / ZK222584）组合使用的POSTER A I期试验
2. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib [J] . Spraggs C. F., Parham L. R., Song K., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第7期

机译：BIM删除多态性对酪氨酸激酶抑制剂（TKI）帕唑帕尼，舒尼替尼和拉帕替尼治疗实体瘤的不同作用
3. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib [J] . Spraggs C. F., Parham L. R., Song K., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第7期

机译：BIM缺失多态性对酪氨酸激酶抑制剂（TKI）Pazopanib，Sunitinib和Lapatinib治疗实体肿瘤的不同效果
4. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience [O] . Marc R. Matrana, Tharakeswara Bathala, Matthew T Campbell, -1

机译：一线帕唑帕尼治疗后再行血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKI）或雷帕霉素抑制剂（mTORi）靶向治疗的未选患者转移性透明细胞肾细胞癌患者的疗效：单一机构经验
5. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors [O] . Sarker, Debashis, Molife, Rhoda, Evans, T. R. Jeffrey, 2008

机译：口服，多靶点酪氨酸激酶抑制剂TKI258在晚期实体瘤患者中的I期药代动力学和药效学研究

75 POSTER Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors

著录项

相似文献

相关主题

期刊订阅